Ataxion

Ataxion is a discovery-stage biopharmaceutical company developing new therapies for rare, debilitating, and underserved neurological disorders. Located in Cambridge, Massachusetts, Ataxion was founded in April 2013 through an Atlas Venture seed initiative by Dr. Josh Resnick and Dr. David Grayzel, Managing Director of Atlas Venture Development Corporation and a member of Ataxion's board of directors.